EyePoint, Inc. (EYPT) FY2025 10-K Annual Report
EyePoint, Inc. (EYPT) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 5, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
EyePoint, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Clinical-stage biopharma developing sustained intraocular drug delivery therapeutics for serious retinal diseases leveraging proprietary bioerodible Durasert E™ technology
- • New emphasized product: DURAVYU™, a novel multi-mechanism VEGF receptor, PDGF, and IL-6/JAK1 inhibitor in Phase 3 trials for wet AMD and DME, first patient dosed in DME Phase 3 in Feb 2026
- • Strategic shift: Transition from early to pivotal late-stage global Phase 3 trials with enrollment completion in two wet AMD studies (LUGANO, LUCIA) and initiation of two DME studies (COMO, CAPRI)
- • Quantitative metric: Over 900 patients enrolled across two Phase 3 wet AMD trials, additional ~480 patients planned for Phase 3 DME trials; Phase 2 VERONA trial showed +10.3 letters BCVA improvement in subgroup vs +3.0 aflibercept
- • Noteworthy fact: DURAVYU's intracellular multi-MOA acting on VEGF receptors plus anti-inflammatory IL-6 signaling constitutes a new treatment paradigm with potential 6-month sustained delivery reducing treatment burden by over 85%
Management Discussion & Analysis
- • Revenue $31.4M down 28% YoY from $43.3M; product sales fell 50% to $1.6M, license/collab revenues down 57% to $16.7M, royalty income up 708% to $13.0M
- • Operating expenses $274.8M up 45% YoY from $189.1M; R&D $221.0M up 66%, G&A $51.6M down 1%; operating loss $243.4M vs $145.9M, loss margin ~776% vs 337% (loss/net loss ÷ revenue)
- • Best segment: Royalty income $13.0M (+708%); Worst: License/collab revenue down $21.8M to $16.7M
- • Financing: Raised $172.5M via public offering + $11.6M ATM sales; cash and securities $306.1M at year-end; Operating cash outflow $240.1M; no buybacks or dividends disclosed
- • Outlook: Phase 3 DURAVYU trials enrollment complete, data expected mid-2026; first DME patient dosed Feb 2026; settled DOJ investigation in principle with ~$4.7M payment; cash runway into Q4 2027
Risk Factors
- • DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026
- • Clinical trial delay risk: DURAVYU Phase 3 topline data expected in 2026, cash runway extends only into Q4 2027
- • Manufacturing risk: inability to scale DURAVYU production could delay Phase 3 trials and commercialization
- • Competitive risk: approval and market acceptance of DURAVYU may be impacted by alternative wet AMD treatments and generics
- • Liquidity risk: $306.1M cash runway likely sufficient only through Q4 2027, requiring uncertain future capital raises that may dilute shareholders
EyePoint, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$31M
▼ -27.5% YoY
Net Income
-$232M
▼ -77.2% YoY
Operating Margin
-776.0%
▼ -43893bp YoY
Net Margin
-739.4%
▼ -43699bp YoY
ROE
-75.8%
▼ -3689bp YoY
Total Assets
$364M
▼ -13.0% YoY
EPS (Diluted)
$-3.17
▼ -36.6% YoY
Operating Cash Flow
-$240M
▼ -90.2% YoY
Source: XBRL data from EyePoint, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on EyePoint, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.